More patients with advanced melanoma who had progressed on ipilimumab with or without a BRAF inhibitor were able to achieve an objective response when treated with the PD-1 immune checkpoint inhibitor nivolumab than with alternative chemotherapy options, according to the interim analysis results of the CheckMate 037 trial published recently in Lancet Oncology.
MRV Research
Melanoma Institute part of $14m melanoma project grant
Federal Minister for Health, the Hon. Sussan Ley, announced more than $14 million in funding for a research program to study the molecular determinants of risk, progression and treatment response in melanoma.
Melanoma: Targeting Macrophages Increases BRAF Inhibitors’ Effectiveness
MedicalResearch.com Interview with: Russel E. Kaufman, MD (2015). Melanoma: Targeting Macrophages Increases BRAF Inhibitors’ Effectiveness
Melanoma-associated Macrophages Appear to be Crucial for Resistance to BRAF Inhibitors
Researchers from The Wistar Institute discovered that macrophages have a crucial role in melanoma resistance to targeted therapies. The study entitled “BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth” was published in the Clinical Cancer Research by Tao Wang, first author, Meenhard Herlyn and Russel E. Kaufman, co-senior authors, from the Molecular and Cellular Oncogenesis Program at The Wistar Institute in Philadelphia, Pennsylvania, along with colleagues.